Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate Dose-Response Study in Obesity
NCT00236639Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 2000
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of topiramate in obesity (4 arms), sponsored by Johnson & Johnson. Primary endpoint: Percent change in body weight from baseline at 60 weeks. Started Jul 2000; status: completed.
02
Drugs
topiramate
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00236639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236639.